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Mycobacterial diseases are a group of illnesses that cause a considerable number of deaths
throughout the world, regardless of years of public health control efforts. Personalized
medicine is a new but rapidly advancing field of healthcare. Personalized medicine in the
field of mycobacteriology may be applied in the different levels of management such as
prevention, diagnosis, treatment and prognosis. A genetic predisposition and a protein dys-
function study are recommended to tailor an individual approach in mycobacterial
diseases.
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1.1. Mycobacterial disease
Mycobacterial diseases are a group of illnesses that are
caused by the mycobacterium species. They include
Mycobacterium tuberculosis (MTB) complex, nontuberculous
mycobacterium (NTM), and Mycobacterium leprae.
MTB is a member of the MTB complex causes tuberculosis
(TB); other members include Mycobacterium africanum and
Mycobacterium bovis. In 2010, there were 8.8 million (range,
8.5–9.2 million) incident cases of TB worldwide; 1.1 million
(range, 0.9–1.2 million) deaths from TB among human immu-
nodeficiency virus (HIV)-negative people and an additional
0.35 million (range, 0.32–0.39 million) deaths from HIV-associ-
ated TB [1].
NTM are ubiquitous organisms that are prevalent in the
environment. NTM has been isolated from domestic water
supplies, workplaces, and hospitals [2]. Currently, more than
125 different species of NTM exist in the environment, many
of which cause human illness [3]. The prevalence of NTM dis-
eases was reported as 1.6–1.8 per 100,000 individuals in most
industrialized countries. Recent studies proposed that NTM
pulmonary disease is becoming increasingly prevalent in
North America, with annual incidence rates of 13 cases per
100,000 in people P50 years of age [4]. It was speculated that
the burden of NTM disease might soon exceed that of tuber-
culosis in industrialized nations [5].
M. leprae (the bacteria responsible for leprosy) grow slowly
and mainly affect the skin, nerves, and mucous membranes.
Leprosy is still a health problem in some parts of theworld [6].2. Personalized medicine
Personalized medicine is a new but rapidly advancing field of
healthcare. Personalized medicine is about making the treat-
ment as individualized as the disease. It involves identifying
genetic, genomic, proteomic and clinical information in order
to make accurate predictions about a person’s susceptibility
to developing disease, the course of disease and its response
to treatment.
In order for personalized medicine to be used effectively by
healthcare providers and their patients, these findings should
be transformed into precise diagnostic tests and targeted
therapies. This has begun to happen in certain areas of infec-
tious diseases, such as testing patients genetically to deter-
mine their likelihood of having a serious adverse reaction to
HIV medications [7].
Personalized medicine should not be confused with
‘‘genetic medicine’’. Genetics, a field more than 50 years old,
is the study of inheritance of a gene or a group of genes. It
investigates individual genes and their effects on health.
Genetic diseases, seemingly ‘‘simple’’ hereditary disorders,
can be influenced by other genes, as well as by environmental
factors such as diet and exposure to toxins [8].
Genomic and personalized medicine aspire to target more
complex diseases, such as cancer, heart disease, and now
infectious diseases,whichareprimarily influencedbyenviron-
mental factors and their interaction with the human genome.Because these diseases have strong multigene components—
and in some cases the diseases might be caused by errors in
the DNA between genes instead of within genes—they can be
better evaluated using a whole-genome approach. Increasing
concern about confidentiality of genetic data was addressed
by the Genetic Information Non-Discrimination Act of 2008
(GINA) [9] that prohibits the use of genetic/genomic informa-
tion by health insurance companies in order to determine a
person’s eligibility for insurance, or to determine insurance
premiums, as well as by employers in order to make decisions
regarding hiring and firing, assigning jobs, and promoting and
demoting. Because consumers should now be able to obtain
their genome profiles and other genetic information without
fear of retribution, GINA is reinvigorating the field of genomic
testing.
Rapid and affordable single nucleotide polymorphism
(SNP) genotyping over the whole genome is now possible,
allowing for genome mapping uncovering novel associations
not possible with a candidate gene approach.
The genome-wide association studies (GWAS) allocate the
genotyping of the most frequent genetic polymorphism in the
genome without hypothesizing about the genomic location of
the causal variants. The completion of the human genome se-
quence, the deposition of SNPs into public databases, the ra-
pid improvements in SNP genotyping methods and the
International HapMap (haplotype map) project have allowed
the genetic association field to progress to the stage that this
approach is feasible. Previous investigations [10,11] and the
International HapMap project have shown that most common
variations in the genome can be represented by approxi-
mately 300,000 SNPs in White populations [12]. African and
other populations with greater variation and less linkage dis-
equilibrium need more SNPs to ensure coverage of the entire
genome [13].
The development of the above techniques to accurately as-
sess diagnostic and prognostic profiles and select patients
with mycobacterial diseases who will respond to a given ther-
apeutic agent is highly desirable and is the foundation for the
future delivery of personalized medicine.2.1. Personalized medicine in mycobacterial diseases
The idea that mycobacterial disease is not only influenced by
bacterium but also by both genetic and environmental factors
was formally stated 59 years ago [14]. At the time it was stated
in reference to TB, but new studies have suggested that it ap-
plies to NTM as well.
While the exposure to NTM is universal and billions of
people have latent tuberculosis infection (LTBI), only a few
persons develop clinical disease [15]. It may be reasonable
to state normal host defense mechanisms must be effective
enough to prevent the infection. The interactions between
mycobacterium and its environment have been suggested.
In a minority of cases there is an obvious identifiable risk fac-
tor such as in the HIV population and immunocompromised
patients, such as those undergoing transplants and chemo-
therapy [3,16]. A substantial proportion of these patients have
no preexisting lung disease and no demonstrable immunode-
ficiency. A small number of NTM are predominantly
Fig. 1 – A strategy for personalized medicine in mycobacterial diseases.
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interaction of genetic and environmental factors causes the
development of clinical mycobacterial disease. However, po-
tential mycobacterium-host interaction at the gene level is
still very limited according to recent studies.
Personalized medicine in the field of mycobacteriology
may be applied in the different levels of management, such
as prevention, diagnosis, treatment and prognosis. The pre-
disposition and protein dysfunction studies are recom-
mended to tailor an individual approach to each patient
(Fig. 1).
Personalized medicine may answer some pertinent ques-
tions, such as:
Who is at risk of contracting LTBI after exposure to MTB?
Who will convert to an active case?
How can the diagnosis, treatment, and prognosis of myco-
bacterial infection be improved?
2.1.1. Who is at risk of contracting LTBI after exposure to MTB?
Indeed, the exposure to MTB happens in the environment, but
the susceptibility to infection is a personal phenomenon.Many investigations have confirmed that genetic factors
are involved in whether or not one is susceptible to mycobac-
terial disease, and these investigations include results from
adoption studies, twin studies, genome-wide linkage and
population-based, case–control association studies [18].
Recently, an association was reported between NTM lung
disease and the polymorphisms of the natural resistance-
associated macrophage protein 1 gene [19].
This finding could raise the possibility of genetic suscepti-
bility for patients with NTM lung disease. Afterward, toll-like
receptors-2 (TLRs) [20], Interleukin-12 receptor beta-1 [21],
interferon-gamma and interferon-gamma receptor-1 genes
[22] were studied.
The identification of host genetic factors, such as human
leukocyte antigens (HLA) of major histocompatibility complex
and/or cytokines and related receptors associated with sus-
ceptibility or resistance to TB, may provide genetic markers
to predict the development of mycobacterial disease after
exposure to bacteria.
The immune mechanisms in TB have been investigated
and it is known from the IL-12/IL-23/IFN-g pathway, together
with other cytokines and factors, that they are vital for the
immunologic response [23].
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carried out using SNPs associated with mycobacterial disease
[15,24–26]. As a consequence, those studies had limited
potential to uncover novel genomic regions that play a role
in the etiology of mycobacterial disease.
Convincing evidence indicating the importance of IFN-g in
particular in the control of mycobacterial infections has been
found in both experimental and clinical studies [27,28]. IFN-g
receptor genes may play a role here. However, the present
study failed to show an association between IFN-gamma
receptor 1 (IFNGR1) polymorphism and increasing susceptibil-
ity to TB [15], but the mutation in IFNGR2 increased the sus-
ceptibility in sporadic TB patients [29].
Polymorphism in IL-1 [30,31], IL-6 [32], IL-12 and its recep-
tors [33,34], HLA [35,36], vitamin D receptor haplogroups
[24,25], and mitochondrial DNA haplogroups [26] were exten-
sively studied with some promising results.
2.1.2. Who will convert to an active case?
Susceptibility to developing TB disease after exposure is influ-
enced by complex interactions between the host and the
pathogen, and genetic and environmental factors [18].
Several genetic loci are involved in susceptibility to myco-
bacterial disease. Recently, it was shown that the mutation of
a human gene encoding the chemokine (C-C motif) ligand 2
CCL2, which is essential for the recruitment of monocytes
and T-cells, may increase the risk of developing active TB
after exposure [37]. Recently a study showed new genetic tar-
gets which influence the risk of developing active TB among
latently infected individuals by GWAS [38]. Finding the strong
association between potential immune gene polymorphisms
and LTBI will be progress with regard to patient selection for
LTBI treatment in the future.
2.1.3. Personalized medicine may improve diagnosis of
mycobacterial infection
Personalized medicine has improved the diagnostic approach
to latent TB. Interferon-gamma release assays (IGRAs) can lo-
cate the patient’s immunologic response to mycobacterial
tuberculosis-specific antigens. It is a starting point for a per-
sonalized diagnosis of mycobacterial diseases.
Finding the genetic susceptibility to facilitate the occur-
rence of drug-resistant mycobacterium might be another fas-
cinating approach that has not yet been studied.
There is a significant demand for personalized biomarkers
for the diagnosis of NTM infection in humans that needs to be
addressed.
2.1.4 Personalized medicine may change treatment of
mycobacterial infection
Finding personalized biomarkers to best define chemotherapy
protocols, individualized treatment duration, and predict risk
of adverse events with antibiotics would be other interesting
markers for clinicians.
A study showed a polymorphism of the tumor necrosis
factor gene (lymphotoxin A+252G/A genotype) in a pulmonary
tuberculosis patient associated with impaired response to
treatment [39].
Anti-TB drug-related hepatotoxicity is a serious worldwide
medical problem among TB patients. It has been proposedthat the production and elimination of the toxic metabolites
depends on the activities of several enzymes, such as N-acetyl
transferase 2, cytochrome P450 oxidase and glutathione
S-transferase. It was shown that DNA sequence variations or
polymorphisms at those enzymes loci could alter the activities
of enzymes and increase the risk of hepatotoxicity. Since the
prevalence of polymorphisms is different in worldwide popu-
lations, the risk of anti-TB hepatotoxicity varies in the popula-
tions. Thus, the knowledge of polymorphisms at those loci,
prior to medication, may be a useful tool to evaluate the risk
of anti-TB hepatotoxicity [40]. Another study showed that
polymorphism of the N-acetyl transferase 2 gene is a risk
factor for INH-induced hepatotoxicity [41].
2.1.5. Personalized medicine may improve prognosis of
mycobacterial infection
The results of a recent study demonstrated that genetic poly-
morphisms of the IL-12+ IFN-g pathway may individually or
jointly contribute to the prognosis of pulmonary TB [42].
Importantly, personalized medicinewill help to bridge cur-
rent treatment goals (bacteriologic cure) with patient cure.
Currently, TB is treated and classified based on bacteriology
response. However, the organ damage such as pulmonary
fibrosis and its consequence effects are not explored enough.
The current TB treatment must focus on a patient cure strat-
egy other than cleaning mycobacterial agents from the body.
The biomarkers should be located to predict pulmonary fi-
brotic changes after TB treatment to reach this goal.
Conclusion
The future needs to include the stratification of mycobacte-
rial-infected patients with personalized biomarkers in order
to reach management goals. The inconsistent treatment re-
sults in different studies come from heterogeneity of patients
with different genetic pools. Personalized medicine may orga-
nize the diagnosis and treatment strategies making it possible
to deliver a better quality of healthcare to patients.
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